InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Boyle Kevin S. Sr., Chief Executive Officer. Director active across 2 companies, notably Ziopharm Oncology INC. Cumulatively, 6 reports have been published. Breakdown: 2 buys · 1 sell. Total volume traded: €11k. Activity tracked since 30 August 2021. The latest transaction was filed on 1 September 2023 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations6 total
68,014 shares@ US$0.140316.3% of flowCommon StockSEC:0000950170-23-046504:0
18,750 shares@ US$2.4183.7% of flowCommon StockSEC:0000899243-22-030186:0
884 shares@ US$1.4050.0% of flowCommon StockSEC:0001209191-21-065138:0
Ideal exit: 13 Aug 2022 (T+270)
884 shares@ US$1.4050.0% of flowCommon StockSEC:0001209191-21-065138
Ideal exit: 13 Aug 2022 (T+270)
875,000 shares0Common StockSEC:0001209191-21-054089:0
875,000 shares0Common StockSEC:0001209191-21-054089
6 of 6 declarations
About Boyle Kevin S. Sr.
Kevin S. Boyle Sr. is the Chief Executive Officer of ZioPharm Oncology Inc. As CEO, he is responsible for the strategic direction of the company, overseeing operations and growth initiatives. His leadership is essential for the organization's success.
